• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    BioMarin Announces Several Oral and Poster Presentations

    Investing News Network
    Sep. 08, 2016 02:32AM PST
    Biotech Investing

    The presentations focus on better understanding the burden of disease in PKU, intracerebroventricular (ICV) delivery and the multi- disciplinary management of CLN2 disease and the impact of treatment on adults with Morquio A syndrome, an MPS disease.

    SAN RAFAEL, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) — BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that two oral and 16 poster presentations related to the company’s products and product candidates will be made at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2016 Annual Meeting, which will be held on September 6-9 in Rome, Italy.  These 18 presentations at SSIEM cover a range of areas in rare genetic diseases, including Phenylketonuria (PKU), Mucopolysacchardosis (MPS) and CLN2 disease, a form of Batten disease.  The presentations focus on better understanding the burden of disease in PKU, intracerebroventricular (ICV) delivery and the multi- disciplinary management of CLN2 disease and the impact of treatment on adults with Morquio A syndrome, an MPS disease.
    Updated long-term data from an extension study of Brineura™ (cerliponase alfa), a recombinant human tripeptidyl peptidase 1 (rhTPP1) to treat children with CLN2 disease, will be presented during an oral platform session. CLN2 disease is a rapidly progressing, fatal neurodegenerative disease with no approved treatments, where the majority of affected children lose their ability to walk and talk by approximately six years of age. Brineura is an enzyme replacement therapy designed to restore TPP1 enzyme activity and break down the storage materials that cause the disease. Brineura is currently under review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act goal date of April 27, 2017. BioMarin also has submitted a Marketing Authorization Application to the European Medicines Agency for Brineura, and it is undergoing validation at the Agency.
    In addition, updated four year results of the long-term safety and efficacy of pegvaliase to treat adults living with phenylketonuria (PKU) will also be presented during an oral session. PKU is a rare genetic condition in which the body cannot metabolize the essential amino acid phenylalanine. Pegvaliase is an enzyme substitution therapy that is designed to substitute phenylalanine ammonia lyase for phenylalanine hydroxylase, the enzyme deficient in people living with PKU. BioMarin intends to submit a marketing application by the first quarter of 2017.
    Additionally, data from 16 abstracts spanning CLN2 disease, mucopolysaccharidosis, PKU, and Pompe disease will be presented.

    Oral Presentations

    Intracerebroventricular cerliponase alfa (BMN 190) in children with CLN2 disease: Results from a Phase 1/2, open-label, dose-escalation study   Presentation: Thur., Sept. 8, 2016
    10:30 am – 12:00 pm
    Authors: A Schulz
    Evaluation of long-term safety and efficacy of pegvaliase treatment for adults with phenylketonuria: updated year 4 results
    Presentation: Thur., Sept. 8, 2016
    13:15 – 14:45 pm
    Authors: N Longo

    Poster presentations:

    Expert opinion on the management of Intracerebroventricular (ICV) drug delivery
    Authors: I Slavc, JL Cohen-Pfeffer, S Gururangan, E Jurecki, J Krauser, T Lester, D Lim, M Maldaun, C Schwering, AJ Shaywitz, M Westphal
    Expert opinion on the management of CLN2 disease
    Authors: N Specchio, RE Williams, HR Adams, M Blohm, JL Cohen-Pfeffer, E de los Reyes, J Denecke, K Drago, C Fairhurst, M Frazier, N Guelbert, S Kiss, A Kofler, J Lawson, L Lehwald, M Leung, S Mikhailova, JW Mink, M Nickel, R Shediac, K Sims, M Topcu, I von Löbbecke, A West, A Schulz
    Expert recommendations for the laboratory diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): diagnostic algorithm and best practice guidelines for a timely diagnosis
    Authors: E Izzo, M Al-Sayed, D Burke, J Cohen-Pfeffer, JD Cooper, L Dvořáková, M Fietz, R Giugliani, H Jahnova, Z Lukacs, S Mole, I Noher de Halac, D Pearce, A Schulz, N Specchio, W Xin, N Miller
    Design and rationale of the study programs for BMN 250, a novel Enzyme Replacement Therapy (ERT) for Sanfilippo B syndrome
    Authors: A Shaywitz, M Oh, S Kent
    Dramatic mobility improvement on galsulfase ERT: a case report
    Authors: J Zakharchuk
    Clinical outcomes from a sub-analysis of adults with Morquio A in a long-term extension study of elosulfase alfa treatment
    Authors: D Hughes, R Giugliani, N Guffon, AS Jones, KE Mengel, R Parini, R Matousek, E Jurecki, A Quartel
    Morquio A Registry Study (MARS): design and baseline characteristics of enrolled patients
    Authors: N Guffon, G Baujat, MB Bober, BK Burton, L Clarke, P Garcia, R Giugliani, CJ Hendriksz, C Lavery, J Raiman, E Jurecki, Z Sisic, A Waite
    National study to assess current practices of the management of phenylketonuria
    Authors: F Rohr, ER Jurecki, S Cederbaum, J Kopesky, A Sanchez-Valle, K Viau, JL Cohen-Pfeffer

    Neuropsychiatric concomitant medications and comorbidities in individuals with Phenylketonuria: findings from the PKUDOS Registry
    Authors: S Waisbren, J Zambrano, M Grant, B Cheng, S Parker, D White, JL Cohen-Pfeffer
    Case-control study of neuropsychological results in patients with mild hyperphenylalaninemia (MHP)
    Authors: A Belanger-Qunitana, B Zamora
    Neuropsychological and quality of life outcomes in untreated adults with mild hyperphenylalaninemia with phenylalanine levels between 360 and 600 µmol/L
    Authors: A Feigenbaum, A Wilson, L Nagy, K Siriwardena, E Nasr, E Kerr
    Phase 3 PRISM-1 and PRISM-2 clinical trial results: to evaluate the efficacy and safety of pegvaliase for the treatment of adults with phenylketonuria (PKU)
    Authors: C Harding, S Amato, J Vockley, K Wierenga, H Li, D Bilder, B Burton, D Dimmock, N Longo, J Posner, JA Thomas, R Zori, O Rosen, F Greblikas, Z Gu, M Li, M Merilainen, HH Weng, H LevyPhase
    3 PRISM-2 long-term extension study evaluating efficacy and safety of pegvaliase for treatment of adults with phenylketonuria 
    Authors: H Levy, C Harding, N Longo, D Bilder, B Burton, R Zori, J Posner, JA Thomas,  J Olbertz, O Rosen, Z Gu, M Merilainen, HH Weng, D Dimmock
    The sixth interim analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER): pregnancies
    Authors: F Feillet, FB Lagler, J Alm, AC Muntau, A Burlina, A Belanger-Qunitana, I Alvarez, A Champigneulle, FK Trefz
    The sixth interim analysis of the Kuvan® Adult Maternal Paediatric European Registry (KAMPER): interim results in PKU and BH4 deficiency patients
    Authors: AC Muntau, FB Lagler, F Feillet, J Alm, A Burlina, A Belanger-Qunitana, I Alvarez, A Champigneulle, FK Trefz, FJ Van Spronsen
    Long-term efficacy and safety of reveglucosidase alfa in subjects with late-onset Pompe Disease: 144-week follow-up of the POM-001/002 Studies
    Authors: T Geberhiwot, B Byrne, BA Barshop, R Barohn, D Hughes, D Bratkovic, C Desnuelle, P Laforet, E Mengel, M Roberts, P Haroldsen, L Smith, K Yang, L Walsh
    About BioMarin
    BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company’s portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
    For additional information, please visit www.BMRN.com. Information on BioMarin’s website is not incorporated by reference into this press release.

    BioMarin® and Kuvan® are registered trademarks and Brineura™ is a trademark of BioMarin Pharmaceutical Inc.

    Don’t forget to follow us @INN_LifeScience for real-time news updates.

    pompe diseaseorphan diseasesbiomarin pharmaceuticalmarketing authorizationfood and drug administrationneurodegenerative diseaseclinical trial results
    The Conversation (0)

    Go Deeper

    AI Powered
    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×